MIPOMERSEN: A NOVEL THERAPEUTIC DRUG FOR THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA, HYPERLIPIDAEMIA, AND HYPERCHOLESTEROLEMIA
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2016, Vol 8, Issue 3
Abstract
Familial Hypercholesterolemia (FH) is one of the most common autosomal dominant disorders which exist in either heterozygous form or a homozygous form. These two forms are prevalent in1 in500 and1 ina million population respectively. FH results in premature atherosclerosis; as early as childhood in case of homozygous (HoFH) form and in adults in case of heterozygous (HeFH) form. In case of HoFH both the alleles forLDL-receptor are defective, whereas the mutation in the single allele is the cause for HeFH. Both the forms of the disease are associated with high levels ofLDL-C and lipoprotein (a) in plasma, with high morbidity and mortality rate caused by cardiovascular disease. In several past years, different lipid-lowering drugs like Statins (HMG-coenzyme-A reductase inhibitor), MTTP inhibitor, CETP inhibitors, PCSK9 inhibitor, thyroid mimetics, niacin, bile acid sequestrants and lipid apheresis were administered to patients with FH, to achieve the goal of reducing plasmaLDL-C and lipoprotein (a). However, such drugs proved inefficient to achieve the goals because of several reasons. Mipomersen is a 20 nucleotide antisense oligonucleotide; a novel lipid-lowering therapeutic drug currently enrolled in the treatment of patients with HoFH, HeFH and other forms of hypercholesterolemia. It arrests the synthesis of Apo B100 by targeting Apo B100 mRNA and thus inhibiting the synthesis and release of all Apo B-containing lipoproteins, such as very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low-density lipoprotein (LDL), and non-high-density lipoprotein. It also lowers lipoprotein (a), and ultimately reduces the severity of coronary artery disease and cardiovascular disease.Keywords: Hypercholesterolemia, Low-density lipoprotein, Mipomersen, Cholesterol, Lipoprotein, Antisense oligonucleotideÂ
Authors and Affiliations
Ajay Kumar, Arun Acharya, Dinobandhu Nandi, Neha Sharma, Ekta Chitkara
Keywords
Related Articles
- EP ID EP577760
- DOI -
- Views 55
- Downloads 0
CANAL DISH (CD), THE NEW ANTIMICROBIAL TESTING APPARATUS
Objective: This writing aims to introduce new antimicrobial test apparatus called Canal Dish (CD), theoretically.Methods: We have designed two types of CD such as Circular CD (CCD) and Square CD (SCD). Internally, the CC...
EPIDEMIOLOGICAL STUDIES ON VARYING EXTENDED-SPECTRUM β-LACTAMASES PRODUCING UROPATHOGENIC BACTERIA
Objective: Urinary tract infection (UTI) is the most common serious infection during infancy, adult male and female, as well as at the time of pregnancy. UTI is also the most common nosocomial infection in many hospitals...
LIGAND BASED PHARMACOPHORE MODELING, VIRTUAL SCREENING AND MOLECULAR DOCKING STUDIES TO DESIGN NOVEL PANCREATIC LIPASE INHIBITORS
Objective: To understand the essential structural features required for pancreatic lipase (PL) inhibitory activity and to design novel chemical entities, ligand-based pharmacophore modeling, virtual screening and docking...
PHENOLIC CONTENTS, ANTIBACTERIAL AND ANTIOXIDANT ACTIVITIES OF FLOWER, LEAF AND STEM EXTRACTS OF FERULAGO ANGULATA (SCHLECHT) BOISS
Objective: Ferulago angulata known as Chavir is an Iranian endemic plant that has been used as the food preservative and natural flavor since long times. In the present study, antibacterial and antioxidant activities o...
NEW FLAVONOID COMPOUND FROM ALLIUM HOOKERI THWAITES AS A GASTROPROTECTIVE AGENT
Objective: The main objective of this study was to investigate the antiulcer potential of an isolated flavonoid compound from Allium hookeri (AH).Methods: Oral administration of ethanol-induced ulcer to the mucosal layer...